Results 101 to 110 of about 312,196 (386)

EFFICACY OF THERAPY WITH INDIRECT ANTICOAGULANTS: ROLE OF THE FOODSTUFF VITAMIN K CONTENTS

open access: yesРациональная фармакотерапия в кардиологии, 2016
The anticoagulants of indirect action during many years serve drugs of basic prophylaxis and therapy of thromboembolic episodes at cardiovascular , neurological, oncology, orthopaedic and other diseases, after surgical interventions and traumas, and also
A. P. Momot   +2 more
doaj   +1 more source

Extensive Pulmonary Embolism in late pregnancy associated with Anticardiolipin Antibodies [PDF]

open access: yes, 2004
The leading cause of morbidity and mortality during pregnancy and the puerperium is venous thromboembolism. Though uncommon, the risk is five times higher in a pregnant woman than in a non-pregnant woman of similar age.1,2 In pregnancy, all three ...
Brincat, Mark P.   +5 more
core  

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis [PDF]

open access: yes, 2002
Hormone replacement therapy (HRT) increases the risk of venous thrombosis. We investigated whether this risk is affected by carriership of hereditary prothrombotic abnormalities.
A. Rumley   +26 more
core   +1 more source

Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension

open access: yesArthritis &Rheumatology, EarlyView.
Objective Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE has not been clarified.
Shuliang Jing   +9 more
wiley   +1 more source

Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles [PDF]

open access: yes, 2016
Correspondenc
Adesanya, M. Adeola   +5 more
core   +1 more source

Prevention of Venous Thromboembolism in 2020 and Beyond

open access: yesJournal of Clinical Medicine, 2020
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE).
Matthew Nicholson   +3 more
semanticscholar   +1 more source

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar   +35 more
wiley   +1 more source

Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline [PDF]

open access: yes, 2016
The American Physical Therapy Association (APTA), in conjunction with the Cardiovascular & Pulmonary and Acute Care sections of APTA, have developed this clinical practice guideline to assist physical therapists in their decision-making process when ...
Auten, Beth   +5 more
core   +1 more source

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

open access: yes, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy